Other content in this Stream
Prometic Corporate Presentation August 2019
Prometic reports first subject dosed in phase I clinical study with single ascending doses of PBI-4547
PBI-4547 is a novel, orally active immune-metabolic agent which displays antidiabetic, antihyperlipidemic, anti-inflammatory and anti-fibrotic activity as shown in multiple animal models.
Prometic Life Sciences to present at H.C. Wainwright & Co. 21st Annual Global Investment Conference
Members of the management team will provide a business overview and update at the H.C. Wainwright & Co. 21st Annual Global Investment Conference at 11:15 EDT on Tuesday, September 10, 2019 in New York
Prometic Life Sciences Announces Intention to change name to Liminal BioSciences Inc.
Prometic announced today its intention to change its name as part of a global rebrand in support of its new vision and values.
Annual Report 2018
2018 was once again a year filled with strong scientific and clinical program development achievements for Prometic.
Quarterly Report 2018 Q3
Successful Type C meeting with FDA: agreement on proposed plan of action for RyplazimTM (plasminogen) manufacturing process along with Substantial reduction in R&D costs of up to $30 million.
Quarterly Report Q2 2018
Advanced multiple initiatives aimed at extending cash runway, including ongoing partnering discussions related to both PBI-4050 and RyplazimTM (plasminogen).
Board of Directors Charter 2019
Position Description Lead Independent Director 2019
HR & Corporate Governance Committee Charter 2019
Prometic Articles of Incorporation 2019
Prometic Life Sciences Inc. articles of incorporation and articles of amendments
Plasminogen Replacement Therapy for Congenital Plasminogen Deficiency
At Prometic Life Sciences we are committed to addressing unmet medical needs in rare diseases such as Congenital Plasminogen Deficiency (PLGD).
Virtual Tour of Prometic Life Science's Manufacturing Process
You will discover how our industry leading technology is now being used to extract and purify therapeutic proteins from human plasma to provide for the development of best in class products.
Joe Parker, MD: PBI-4050 Demonstrates Promising Efficacy Results for IPF Treatment